DSM Joins International Response to Flooding in Australia
DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV (DSM KON, Euronext) today announced a contribution of $10,000 to the Premier's Disaster Relief Appeal launched to help Queensland residents affected by the recent floods
PARSIPPANY, N.J., Jan. 27, 2011 /PRNewswire/ -- Significant flooding occurred in many areas of Queensland during late December 2010 and early January 2011. Thousands of residents were affected. A disaster relief appeal, the 'Premier's Disaster Relief Appeal', was launched on 29 December 2010, by Premier of Queensland, Anna Bligh. DSM recognizes the efforts of Queenslanders who pitched in to help their fellow citizens clean-up in the wake of the floods and help families in need, many of whom lost everything.
In May of 2010 DSM announced the signing of agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane. Currently under construction the facility will be located on the Princess Alexandra Hospital Campus, 5.5 kilometers from the center of Brisbane. Karen King, President of DSM Biologics commented, "We are extremely concerned about the effects of the severe flooding in Queensland and the need for support of those impacted."
Professor Peter Gray, Director of the Australian Institute of Bioengineering & Nanotechnology which is based in Queensland, visited DSM soon after the flooding. According to Professor Gray, "The relief appeal will make a significant difference by helping many in need as Queensland battles to recover from the flooding. I am delighted to have DSM among our supporters." Alexander Wessels, President and CEO, DSM Pharmaceutical Products, stated, "As a responsible corporate citizen around the world, DSM is committed to the communities in which we work and live. This is our humble gesture to aid those in need through the auspices of the Premier's appeal."
For more information about supporting the Premier's Disaster Relief Appeal, visit www.qld.gov.au/floods/
DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com
For more information:
Director, marketing and Communications
tel. +1 973 257 8160
DSM Forward-looking statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
SOURCE DSM Pharmaceutical Products
More by this Source
DSM and Tunitas Therapeutics Sign Agreement to Develop Lead Allergy Therapeutic
Dec 03, 2013, 11:00 ET
DSM and Opthea Sign Agreement to Manufacture Opthea's Lead Product for Eye Disease
Oct 29, 2013, 17:55 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.